Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Emerging drugs for cancer-related pain.

Literature DB >> 21938596

Emerging drugs for cancer-related pain.

Sebastiano Mercadante.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2011 PMID： 21938596 DOI： 10.1007/s00520-011-1281-y

Source DB: PubMed Journal: Support Care Cancer ISSN： 0941-4355 Impact factor: 3.603

× No keyword cloud information.

41 in total

1. Why are our patients still suffering pain?

Authors: Sebastiano Mercadante
Journal: Nat Clin Pract Oncol Date: 2007-03

Review 2. Systematic review and meta-analysis of cannabis treatment for chronic pain.

Authors: Eva Martín-Sánchez; Toshiaki A Furukawa; Julian Taylor; Jose Luis R Martin
Journal: Pain Med Date: 2009-09-01 Impact factor: 3.750

Review 3. Tapentadol hydrochloride: a centrally acting oral analgesic.

Authors: William E Wade; William J Spruill
Journal: Clin Ther Date: 2009-12 Impact factor: 3.393

Review 4. Translational pain research: achievements and challenges.

Authors: Jianren Mao
Journal: J Pain Date: 2009-07-22 Impact factor: 5.820

5. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.

Authors: Winfried Meissner; Petra Leyendecker; Stefan Mueller-Lissner; Joachim Nadstawek; Michael Hopp; Christian Ruckes; Stefan Wirz; Wolfgang Fleischer; Karen Reimer
Journal: Eur J Pain Date: 2008-08-31 Impact factor: 3.931

6. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study.

Authors: Russell K Portenoy; Jay Thomas; Michele L Moehl Boatwright; Diep Tran; Frank L Galasso; Nancy Stambler; Charles F Von Gunten; Robert J Israel
Journal: J Pain Symptom Manage Date: 2008-05 Impact factor: 3.612

Review 7. Translational medicine: cancer pain mechanisms and management.

Authors: A Delaney; S M Fleetwood-Walker; L A Colvin; M Fallon
Journal: Br J Anaesth Date: 2008-05-19 Impact factor: 9.166

8. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.

Authors: Richard L Rauck; Marvin Tark; Eva Reyes; Teresa G Hayes; Anthony J Bartkowiak; David Hassman; Srinivas Nalamachu; Rob Derrick; Julian Howell
Journal: Curr Med Res Opin Date: 2009-12 Impact factor: 2.580

9. Effects of ralfinamide, a Na+ channel blocker, on firing properties of nociceptive dorsal root ganglion neurons of adult rats.

Authors: Hana Yamane; William C de Groat; Adrian Sculptoreanu
Journal: Exp Neurol Date: 2007-07-19 Impact factor: 5.330

10. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.

Authors: S Mercadante; L Radbruch; A Davies; P Poulain; T Sitte; P Perkins; T Colberg; M A Camba
Journal: Curr Med Res Opin Date: 2009-11 Impact factor: 2.580

3 in total

1. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.

Authors: Keiichiro Imanaka; Yushin Tominaga; Mila Etropolski; Hiroki Ohashi; Keiichiro Hirose; Taka Matsumura
Journal: Clin Drug Investig Date: 2014-07 Impact factor: 2.859

2. Cancer pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: results from a non-interventional study.

Authors: Thomas Nolte; Ulf Schutter; Oliver Loewenstein
Journal: Pragmat Obs Res Date: 2013-12-19

3. Incidence of opioid-induced constipation in Japanese patients with cancer pain: A prospective observational cohort study.

Authors: Akihiro Tokoro; Hisao Imai; Soichi Fumita; Toshiyuki Harada; Toshio Noriyuki; Makio Gamoh; Yusaku Akashi; Hiroki Sato; Yoshiyuki Kizawa
Journal: Cancer Med Date: 2019-06-24 Impact factor: 4.452

3 in total